Neutralizing Epitopes on the Extracellular Interferon g
Receptor (IFNgR) a-Chain Characterized by Homolog
Scanning Mutagenesis and X-ray Crystal Structure of
the A6 FabÂ±IFNgR1-108 Complex
Satoshi Sogabe2
, Fiona Stuart
1
, Christoph Henke1
, Angela Bridges1
Geoffrey Williams1
, Ashley Birch1
, Fritz K. Winkler2
*
and John A. Robinson1
1
Department of Chemistry
University of Zurich
Winterthurerstrasse 190
8057, Zurich, Switzerland
2
F. Hoffmann-La Roche Ltd
Pharmaceutical Research-New
Technologies, 4070, Basel
Switzerland
The extracellular interferon g receptor a-chain comprises two immunogloï¿¾bulin-like domains, each with Â®bronectin type-III topology, which are
responsible for binding interferon g at the cell surface. The epitopes on
the human receptor recognized by three neutralizing antibodies, A6,
gR38 and gR99, have been mapped by homolog scanning mutagenesis. In
this way, a loop connecting b-strands C and C0 in the N-terminal domain
was identiÂ®ed as a key component of the epitopes bound by A6 and
gR38, whereas gR99 binds to the C-terminal domain in a region including
strands A and B and part of the large C0
E loop. The epitope for A6 was
conÂ®rmed in a crystal structure of a complex between a recombinant
N-terminal receptor domain and the Fab fragment from A6, determined
by X-ray diffraction to 2.8 AÃŠ resolution. The antibody Â±antigen interface
buries 1662 AÃŠ 2 of protein surface, including 22 antibody residues from
Â®ve complementarity determining regions, primarily through interactions
with the CC0 surface loop of the receptor. The Â¯oor of the antigen bindï¿¾ing cavity is formed mainly by residues from CDR L3 and CDR H3
while a surrounding ridge is formed by residues from all other CDRs
except L2. Many potential polar interactions, as well as 13 aromatic sideï¿¾chains, four in VL, six in VH and three in the receptor, are situated at the
interface. The surface of the receptor contacted by A6 overlaps to a large
extent with that contacted by interferon-g, in the ligand Â± receptor comï¿¾plex. However, the conformation of this epitope is very different in the
two complexes, demonstrating that conformational mobility in a surface
loop on this cytokine receptor permits steric and electrostatic complemenï¿¾tarity to two quite differently shaped binding sites.
# 1997 Academic Press Limited
Keywords: cytokine; antibody Fab fragment; molecular recognition;
*Corresponding author induced Â®t; surface plasmon resonance biosensor
Introduction
The powerful antiproliferative, immunomodulaï¿¾tory and antiviral activities of interferon g (IFNg)
are initiated following association of the cytokine
with a membrane-bound receptor present on many
cell types (Bach et al., 1997). The human IFNgR, a
member of the hematopoietic cytokine receptor
Abbreviations used: CDR, complementarity determining region; CH1, the Â®rst constant domain of the heavy chain;
CL, constant domain of the light chain; EPO, erythropoietin; EPOR, erythropoietin receptor; FBN-III, Â®bronectin typeï¿¾III; Fchl, the heterodimer CL Â‡ CH1; Fv, the heterodimer VH Â‡ VL; HIV-1, human immunodeÂ®ciency virus type 1;
IFNg, interferon g; IFNgR, interferon g receptor a-chain; GRH, growth hormone; GRHR, growth hormone receptor;
Ig, immunoglobulin; mAb, monoclonal antibody; PCR, polymerase chain reaction; PRL, prolactin; PRLR, prolactin
receptor; SPR, surface plasmon resonance; Trx, thioredoxin from Escherichia coli; TF, tissue factor; VH, VL, variable
domains of the heavy (H) and light (L) chain; wt, wild-type; CD, circular dichroism; r.m.s., root mean square; IPTG,
isopropyl-b,D-thiogalactoside; PMSF, phenylmethylsulfonyl Â¯uoride.
J. Mol. Biol. (1997) 273, 882Â±897
0022Â±2836/97/440882Â±16 $25.00/0/mb971336 # 1997 Academic Press Limitedsuperfamily, comprises an extracellular portion of
229 residues, a single transmembrane region of 22
residues, and a cytoplasmic domain of 221 resiï¿¾dues. The crystal structure, recently reported
(Walter et al., 1995), of recombinant extracellular
human IFNgR in a 2:1, receptor:ligand complex
with IFNg revealed in atomic detail how the extraï¿¾cellular portions of two IFNgR chains bind the
homodimeric (2  17 kDa) IFNg at the cell surface.
Other cytokine receptor superfamily members
whose crystal structure in a complex with a recepï¿¾tor ligand have also been reported include the
receptors for GRH (De Vos et al., 1992), PRL
(Somers et al., 1994), EPO (Livnah et al., 1996), IL-1
(Schreuder et al., 1997; Vigers et al., 1997) and TF
(Banner et al., 1996). An additional transmembrane
IFNgR b-chain (or accessory factor), however, is
necessary for species speciÂ®c signal transduction
by IFNg (Marsters et al., 1995), and it is not yet
clear from a structural viewpoint how this b-chain
interacts with the IFNgÂ± (IFNgR)2 complex.
There is currently great interest in the mechanï¿¾isms of ligand recognition by members of the cytoï¿¾kine receptor superfamily. The cytokine binding
sites are, in several cases, formed by a small set of
closely spaced surface loops that extend from a
b-sheet core, much like the antigen binding sites on
antibodies. Crystallographic studies on GRHR,
PRLR, IFNgR and EPOR have indicated that the
ability of these receptors to speciÂ®cally recognize
different ligands may arise through sequence
diversity in the surface loops, as well as through
local and global conformational diversity
(Kossiakoff et al., 1994). In the work described
here, recognition of the extracellular IFNgR by
three surrogate ligands, in the form of neutralizing
mAbs (denoted A6 (Aguet & Merlin, 1987), gR38
and gR99 (Garotta et al., 1990)) has been studied.
These three mAbs inhibit binding of human IFNg
to native and recombinant human IFNgR. It was,
therefore, of interest to enquire how the structural
epitopes bound by these neutralizing mAbs, and
the mechanisms of their recognition by the recepï¿¾tor, are related to those involved in IFNg binding.
The extracellular IFNgR monomer comprises
two domains (domain D1 from residue 14-102, and
domain D2 from residue 114-221){, each resemï¿¾bling an Ig fold with FBN-III topology. In each
domain, the chain forms two antiparallel b-sheets
composed of b-strands A, B, E and G, F, C and C0
(Figure 1). The interdomain angle between D1 and
D2 is approximately 120 in the IFNgR, which is
similar to that seen in TF, but greater than the
90 angle observed between the corresponding
domains in the GRHR, the PRLR and the EPOR.
The domain linker in the IFNgR chain (residues
103 to 113) includes a helical turn, similar to that
seen in GRHR, PRLR, TF and EPOR, but contains
a cysteine residue (Cys105) that forms a disulÂ®de
bridge with Cys150 located in the BC loop in D2.
This disulÂ®de is buried in the extensive interdoï¿¾main interface.
Equivalent residues on each extracellular IFNgR
chain bind identical 2-fold related surfaces on the
IFNg homodimer in the 1:2, ligand:receptor comï¿¾plex. These include residues in the CC0 and EF
loops, and the F and G b-strands of D1, the helical
turn in the linker, and the BC and FG loops from
D2. As noted earlier (Walter et al., 1995), aromatic
receptor residues (Tyr49, Trp207 and Trp82) conï¿¾tribute almost one-third of the total buried surface
area (total 960 AÃŠ 2
) in each binding interface.
Here, the epitopes on the extracellular human
IFNgR recognized by A6, gR38 and gR99 have
been characterized by homolog scanning mutagenï¿¾Figure 1. Ribbon representation of the extracellular
IFNgR drawn using MOLMOL (Koradi et al., 1996) and
the coordinates of one receptor chain from the IFNgÂ±
IFNgR complex. The two b-sheets, comprising strands
A, B, E and C0
, C, G, F of each domain are indicated,
together with the N and C termini. The balls represent
the positions of Cys residues (the Cb atoms) involved in
disulÂ®de bridges.
{ The IFNgR chain is numbered sequentially
assuming residues Glu1Met2Gly3.... correspond to the N
terminus of the mature receptor after cleavage of the
signal peptide (Aguet et al., 1988). VH and VL of mAb
A6 are numbered according to Kabat et al. (1991), as
given earlier (Bridges et al., 1995). Antibody residues are
named as follows: residue-type H(or L)-chain;residue
number. Residues in the recombinant IFNgR1-108 chain
have the preÂ®x I.
Epitopes on the Interferon  Receptor 883 esis (Cunningham et al., 1989). In addition, a crysï¿¾tal structure has been determined to 2.8 AÃŠ resolï¿¾ution of a complex formed between an Fab
fragment derived from A6 and a recombinant D1
of the IFNgR (residues 1 to 108 with a Cys105Ser
mutation, and an additional two residues (Val-Pro)
at the N terminus, denoted here IFNgR1-108). A6
and gR38 were shown earlier to bind overlapping
epitopes located in IFNgR1-108
, whereas gR99 recogï¿¾nizes an epitope within D2 between residues 100
and 229 (Williams et al., 1995). In the A6 Fabï¿¾IFNgR1-108 complex reported here, the CDRs of the
antibody interact primarily with the CC0 surface
loop of the receptor. The antibody epitope thus
overlaps to a large extent the site contacted by
IFNg, in the ligand Â± receptor complex. However,
the conformation of this surface loop is quite differï¿¾ent in the two complexes, providing an example of
how local conformational mobility in a cytokine
receptor permits steric and electrostatic compleï¿¾mentarity to two quite differently shaped binding
sites.
Results and Discussion
Production and mutagenesis of IFNgR
The human extracellular IFNgR residues 1 to 229
(IFNgR1-229
), with a c-myc peptide tag (Evan et al.,
1985) fused to its C terminus, was produced by a
secretion expression system in Escherichia coli. The
afÂ®nities of this protein to the mAbs A6, gR38 and
gR99, as well as to the ligand IFNg10 (DoÃˆbeli
et al., 1988), were compared with those for wt
extracellular IFNgR produced in a baculovirus
expression system (Gentz et al., 1992) using a SPR
biosensor (Pharmacia BIAcore2) (data not shown).
The E. coli-derived IFNgR1-229 has a slightly lower
apparent afÂ®nity for mAbs A6 and gR99; however,
in all cases the differences between E. coli and
insect cell-derived receptor are less than twofold.
The absence of glycosylation in the E. coli-derived
protein is one possible reason for the small differï¿¾ences observed.
The mAbs A6, gR38 and gR99 recognize conforï¿¾mational epitopes on the human IFNgR, but do not
bind mouse IFNgR signiÂ®cantly or the reduced
and denatured human IFNgR (Aguet & Merlin,
1987; Garotta et al., 1990). Homolog scanning
mutagenesis was therefore used to map the epiï¿¾topes recognized by A6, gR38 and gR99 on the
receptor surface. For this purpose, the panel of
mutants shown in Table 1 were prepared using the
E. coli secretion expression system. A comparison
of the human and mouse extracellular receptor
sequences is given in Figure 2.
The CD spectra of all mutants had shapes simiï¿¾lar to that of wt receptor, with a small positive
maximum at 235 nm and a large negative maxiï¿¾mum at 195 nm, essentially as described earlier for
the wt receptor (Fountoulakis & Genz, 1992). This
indicates that the mutants and wt have similar
folds. This conclusion is also supported by the
observation that all N-terminal domain mutants
were bound normally by gR99, whereas all recepï¿¾tors with mutations in the C-terminal domain were
recognized normally by A6, as assayed using the
BIAcore instrument.
The effects of the mutations on binding to A6,
gR38 and gR99 are summarised in Table 1.
Mutants 6 and 8 show a greatly reduced afÂ®nity
for A6 and gR38, mainly due to a decrease in
apparent kon on the biosensor surface (data not
shown). The region altered in mutant 6 correï¿¾sponds to the CC0 loop seen at the interface in the
crystal structure of the A6 Â± IFNgR1-108 complex,
described below. This CC0 loop is, therefore, corï¿¾rectly identiÂ®ed by mutagenesis as an important
part of the A6 conformational epitope.
Beneath the CC0 loop in the A6 Â± IFNgR1-108 crysï¿¾tal structure is a second loop (the EF loop) formed
by residues that are altered in mutant 8. As disï¿¾cussed below, the A6 Fab makes only a few conï¿¾tacts with this EF loop and their disruption may
not be sufÂ®cient to account for the observed loss of
afÂ®nity of mutant 8 with A6. Alternatively, the EF
loop may exert an inÂ¯uence on the conformations
accessible to the CC0 loop when bound to A6,
which may be critically altered in mutant 8. The
mutagenesis results conÂ®rm that the gR38 and A6
epitopes overlap (Williams et al., 1995), and show
that both are located in the region of the CC0 loop.
However, small differences in apparent koff values
between the binding of individual mutants by
these antibodies were observed, although the magï¿¾nitude of the effects were small (4factor of 2; data
not shown). Thus the receptor epitopes bound by
A6 and gR38 are very closely related, but not idenï¿¾tical.
Mutants 13, 14 and 21 are severely disabled in
their afÂ®nity for gR99 (Table 1), whereas, with the
exception of mutants 18 and 20, where the KD
values are reduced by a factor of 5 to 6 in this
assay, the other mutants show close to wt afÂ®nity.
The residues altered in mutants 13, 14 and 21 are
spatially adjacent on one face of the receptor,
deÂ®ned by strands A and B and part of the large
C0
E loop of the C-terminal Ig-like domain. As
shown in Figure 3, this region of the receptor does
not appear to overlap the surface buried in the
IFNg-IFNgR complex. Nevertheless, the intact
mAb (Garotta et al., 1990) and single-chain Fv fragï¿¾ment derived from gR99 (Bridges et al., 1996) were
shown by radioimmunoassay to inhibit IFNg bindï¿¾ing to native receptor on human Raji cells. From a
structural viewpoint, the mechanism of inhibition
by gR99 is unclear. We note, however, that modelï¿¾ing studies (Walter et al., 1995) have suggested that
acidic residues near the C0
E loop (altered in
mutant-21) may be important in binding basic resiï¿¾dues in the C-terminal tail of IFNg. The C-terminal
IFNg residues beyond 122 extend into the solvent
and from the crystal structure do not appear to be
important for receptor binding. However, bioï¿¾chemical assays have shown that Arg129 is an
essential part of a functionally important C-termï¿¾884 Epitopes on the Interferon  Receptorinal IFNg sequence that is required for full receptor
binding afÂ®nity (Haelewyn et al., 1997).
Crystal structure of the A6-IFNgR1-108 complex
The structure of the complex was solved by molï¿¾ecular replacement techniques using search models
for the Fv and Fchl parts of the Fab as described in
Materials and Methods. A summary of the reÂ®neï¿¾ment results is given in Table 2. Interpretation of
the density of the receptor domain was greatly
aided by the availability of a model for this
domain (CheÃ‚ne et al., 1995; le Du et al., unpubï¿¾lished data). The Â®nal distribution of the mainï¿¾chain dihedral angles is presented in a Ramachanï¿¾dran plot in Figure 4. Over 97% of the non-glycine
and non-proline residues lie inside favored or
additional allowed regions as deÂ®ned in PROï¿¾CHECK (Laskowski et al., 1993), which is slightly
better than the distribution expected for a structure
reÂ®ned to 2.8 AÃŠ resolution.
The reÂ®ned model comprises 442 of the 540 resiï¿¾dues present in the complex and 30 well-deterï¿¾mined water molecules (see Table 2). The structure
is well deÂ®ned for the Fv part of the Fab fragment,
for most of the receptor domain and particularly
for the antibody Â± antigen interface, which is the
area of prime interest in this study. However, a
large fraction of the residues in the Fchl part (85 of
203) are very poorly deÂ®ned in the electron density
and have been removed from the model. The Fchl
chain segments that have been retained in the
model still have much higher average B-factors
than the other three domains (Table 2). Neither
domain in Fchl is involved in any crystal contacts
and, given their small interface with the Fv
domains, considerable positional disorder is indiï¿¾cated. As apparent from omit maps (see Materials
Table 1. The apparent dissociation constants (KD), determined on a BIAcore instrument for complexes formed
between the immobilized mAbs A6, gR38 and gR99 and wt and mutant IFNgRs
Antibody A6 Antibody gR38
KD (mut) KD (mut)
Mutant Mutations introduced into IFNgR KD (nM) KD (wt) KD (nM) KD (wt)
IFNgR1-229, wt from E. coli 14.2 Â± 32.9 Â±
1 T14V 13.6 0.96 37.4 1.1
2 T19L, E21K 13.6 0.96 38.0 1.2
3 M25L, I28V 9.9 0.7 24.7 0.8
4 I35N, P37S, V39T, V41I 18.1 1.3 43.0 1.3
5 E45Q 16.8 1.2 57.0 1.7
6 N48V, (G50V51K52), N53S, S54G, E55S I57T 5820 410 >3400 >103
7 A59S, I61T, H65D 16.0 1.1 29.4 0.9
8 S71Y, D72E, H73Q, V74I, G75M, D76Y, S78D, N79V, L81A 2100 148 >2880 >86
9 V83A, R88K 9.9 0.7 36.2 1.1
10 A95D, K98R, E100K 13.1 0.9 37.8 1.2
11 A103L, V104M, R106L, D107K 41.4 2.9 28.9 0.9
gR99
KD (mut)
Mutant Mutations introduced into IFNgR KD (nM) KD (wt)
IFNgR1-229, wt from E. coli 2.7 Â±
12 I110V, K114G 2.7 1.0
13 D116E, i117R, E120K 2360 874
14 K122E, I124L, M125S, I126V, D127L, I128V 130 48
15 S132E, F134V 5.8 2.1
16 D138E, E139S, E141G, V142T 2.4 0.9
17 D138E, E139S, E141G, V142T, D143M, Y144F, D145G, 1.9 0.7
P146D, E147G, T148S
18 I152T, R153F, V154D, N156T 15 5.6
19 R160E, M161H, G163R, i164G 1.6 0.6
20 Q167L, Y168H, K169T, I170K, L171H 17 6.3
21 Q173V, K174E, E175K, D176E, D177E, D179N, I181T, 673 249
Q182L, Q184E
22 A186N, P188S 2.6 1.0
23 S191T, N193D, Q195R 2.3 0.9
24 V198I, A200V, E201D, V203I 4.1 1.5
25 V198I, A200V, E201D, V203I, L204S, H205S, V206F, 4.5 1.7
G208Q, T210R
26 E216D, T220P, I221P, N223H, S224D, S225D, I226R, G228D 1.4 0.5
Response curves consistent with a 1:1 interaction model were only obtained when the mAbs were immobilized (O'Shannessy &
Winzor, 1996). The standard deviation in the kinetic parameters was <25% between repeated analyses with different preparations of
the same protein. The changes introduced into each mutant are indicated. For example, in mutant 1, T14V indicates that residue T14
has been changed to V14. In mutant 6, (G50V51K52), indicates that residues G50V51K52 have been deleted. In mutant 13 i117R
indicates that Arg was inserted after residue 117, and in mutant 19 i164G indicates that Gly was inserted after residue 164 (see
Figure 2). Mutants 1 to 11 bound with wt afÂ®nity to gR99, whereas mutants 12 to 26 bound with wt afÂ®nity to A6 and gR38.
Epitopes on the Interferon  Receptor 885and Methods), the density resulting from averï¿¾aging over all populated states of these disordered
domains still makes a signiÂ®cant contribution to
Bragg scattering. A single structural model with
isotropic B-factors is inadequate to model this denï¿¾sity and the somewhat high R-factor is likely to
result from not modeling this residual density. The
average B-factors of the Fv domains (47 AÃŠ 2
) and of
the receptor antigen (59 AÃŠ 2
) are consistent with an
intrinsic B-factor of 58 AÃŠ 2 of these crystals.
The antigenÂ±antibody interface
As illustrated in Figure 5, the CC0 loop of the
receptor domain reaches into the shallow antigen
binding site formed by the CDRs of the A6 Fab
fragment. The total surface area buried on complex
formation is 1662 AÃŠ 2 (Figure 6), which is similar to
that reported for other antibody Â±protein antigen
complexes (Davies & Cohen, 1996). The HyHEL5Â±
HEL complex constitutes a comparable example
with a buried surface area of 1761 AÃŠ 2 (calculated as
described in Figure 6). Examination of the crystal
contacts shows that the receptor domain also
makes quite an extensive crystal contact with
another symmetry-related VH domain. Compared
to the recognition interface formed by the CDRs as
described below, the buried surface area in this
crystal contact is about 30% smaller (1200 AÃŠ 2
) and
only a few CDR residues on the outside face of VH
contribute.
The spatial arrangement of the many residues
contributing to the extensive antigen Â±antibody
interface is shown in Figures 7 and 8 and the resiï¿¾due Â± residue interactions are schematically repï¿¾resented in Figure 6. The contact surface of the
mAb A6 comprises 22 residues from Â®ve CDRs, 13
and 9 residues from VH and VL, respectively. The
Â¯oor of the binding cavity is formed mainly by
residues from CDR L3 and CDR H3 while the surï¿¾rounding ridge is formed by residues from all
CDRs except L2. The many potential hydrogen
Figure 2. A sequence comparison
of the extracellular parts of the
human and mouse IFNgR. Dashes
indicate a conserved residue. A dot
indicates a residue not present in
the sequence. The locations of the
b-strands are indicated (see
Figure 1).
Figure 3. The epitopes recognized by A6 and gR38 (in red) and gR99 (in blue) on a ribbon representation of the
IFNgÂ±IFNgR complex as determined by le Du et al. (unpublished results). IFNg (2  17 kDa) is shown in pink and
green, the IFNgR in white (N-terminal domain D1) and yellow (C-terminal domain D2) (see Figure 1). The red and
blue regions are those where changes are introduced in mutant 6 (CC0 loop) and 8 (EF loop) (red), and 13 (strand A),
14 (strand B) and 21 (C0
E loop) (blue) (see Table 1).
886 Epitopes on the Interferon  Receptor bonding interactions observed in the interface
(Table 3) indicate that polar interactions are
important for speciÂ®c antigen recognition (open
bars in Figure 6). In addition, many aromatic resiï¿¾dues located in the interface contribute to van der
Waals contacts between the antigen and the antiï¿¾body (Â®lled bars in Figure 6). Indeed, 13 aromatic
side-chains are situated at the interface, four in VL
(TyrL30, TyrL91, TrpL92, TrpL96), six in VH
(TyrH32, TrpH52, TrpH53, TyrH58, TyrH99,
HisH100B) and three in the receptor (TyrI49,
TrpI56, TrpI82). The frequent occurrence of aroï¿¾matic residues, particularly Tyr and Trp, in antiï¿¾body combining sites has been noted (Padlan,
1990; Davies & Cohen, 1996).
The epitope of the receptor fragment is disconï¿¾tinuous but 80% of the contact surface occurs with
residues of its CC0 surface loop (I47 to I56). Resiï¿¾dues from the adjacent loop I76 to I84 contribute
only 13%, and only 7% is contributed by residues
I98 and I99, which make a rather loose contact.
The side-chains of TyrI49 and AsnI53 lie adjacent
on one face of the CC0 loop and constitute the part
of the epitope that reaches deepest into the binding
cavity. The hydroxyl group of the buried tyrosine
makes two hydrogen bonds with residues of CDR
H3 and one face of its phenyl group becomes burï¿¾ied through non-polar contacts with the side-chains
of ArgL32 and TrpL92. One NH bond from the Nd2
atom of the buried AsnI53 is directed towards two
backbone carbonyl oxygen atoms of residues from
CDR L3 (Table 3). The other points to the center of
the six-membered ring of TrpL96 located at the
bottom of the antigen binding site (3.8 AÃŠ from N to
center of ring) and suggests an NH aromatic ring
hydrogen bond (Levitt & Perutz, 1988). Similarly,
the Nz atom of LysI47 is 3.9 AÃŠ from the center of
the six-membered ring of TrpL92. Together with
two hydrogen bonds to the main-chain carbonyl
groups of TrpL96 and AsnI48 a stereochemically
almost optimal hydrogen bonding pattern results
for this (presumably) ammonium nitrogen. Tight
interactions, which include six hydrogen bonds
(Table 3), are also observed between residues
GlyI50, ValI51 and LysI52 and the CDRs of the
heavy chain. In the whole interface there is no
residual electron density, indicating the absence of
ordered solvent molecules, and this is consistent
with the lack of sufÂ®ciently large void volumes.
Structure of the IFNgR fragment
The epitope on the IFNgR1-108 domain recogï¿¾nized by A6 largely overlaps the contiguous surï¿¾face that is recognized by IFNg (Walter et al., 1995).
The overall backbone structures of IFNgR1-108 as
observed in the complexes with mAb A6 and IFNg
are very similar, with the exception of surface loop
(I48 to I54), as illustrated in Figure 9(a). For both
complexes the CC0 loop plays an important role in
recognition fully consistent with the neutralizing
activity of mAb A6. In addition, a signiÂ®cant disï¿¾placement towards the adjacent CC0 loop is seen
Table 2. Results of the crystallographic structure reÂ®nement
Data
Resolution (AÃŠ ) 20.0Â±2.82
R-factor/no. of reflections (all data) 0.255 19,997
R-factor/no. of reflections(|F|>2s(F)) 0.246 18,723
Free R-factor /no. of reflections (|F| > 2s(F)) 0.314 954
Model
No. of non-H atoms
Total 3454
Protein 3424
Solvent 30
No. of residues/no. of missing residues 442 98
Missing residues
IFNgR1-108 13
(I1-I10, I106-I108)
Light chain 46
L120-L133, L148-L157
L178-L192, L208-L214)
Heavy chain 39
(H119-H141, H145-H146,
H165-H166, H193-H206, H222-H223)
Stereochemistry (r.m.s. deviations from ideality)
Bond lengths (AÃŠ ) 0.011
Bond angles (degrees) 1.85
Thermal parameters (isotropic mean B in AÃŠ 2 /no. of atoms)
All 62.1 3454
54.1a 2863
IFNgR1-108 59.2a 669
Fv 47.1a 1748
Fchl 74.2a 446
Solvent 37.0 30
a Atoms with B > 90 AÃŠ 2 were excluded from this analysis.
Epitopes on the Interferon  Receptor 887for the EF loop (residues I76 to I79) in the A6
complex.
In the CC0 loop conformation observed here
(Figure 9(b)), the sheet interaction between strands
C and F is extended by one residue, equivalent to
one additional main-chain hydrogen bond comï¿¾pared to the situation seen in the complex with
IFNg. Additional hydrogen bonding interactions
are also indicated between the carboxamide oxyï¿¾gen of AsnI79 (EF loop) and the main-chain NH
groups of ValI51 and LysI52 of the CC0 loop as
well as between the carboxamide groups of AsnI79
and AsnI48. Finally, four intraloop hydrogen
bonds are seen in the CC0 loop conformation
observed in the A6 complex as compared to only
one in the more open conformation observed in
the complex with IFNg. The more-closed conforï¿¾mation observed here may thus be the preferred
conformation of this loop in the unliganded recepï¿¾tor and the conformation seen in the complex with
IFNg may only be induced upon ligand binding.
However, the conformational change of the CC0
loop correlates with a displacement of the adjacent
EF loop (Figure 9(a)) which, in the intact receptor,
also interacts with residues of the C-terminal recepï¿¾tor domain. For the CC0 loop to occur in the closed
conformation in the unliganded receptor would
thus need some adjustment in these interdomain
interactions to accommodate such a 2 to 3 AÃŠ shift
in the position of the EF loop.
The mAb A6 binds the human IFNgR with high
afÂ®nity, but shows essentially no afÂ®nity to the
rather homologous mouse IFNgR (54% identity).
The three-residue deletion in the CC0 loop of the
mouse receptor (Figure 2) leads to a truncated CC0
loop of the same length and most likely a similar
conformation as observed in TF (Muller et al., 1994;
Harlos et al., 1994). The deleted residues correï¿¾spond to G50 to K52 and, as seen in Figure 6, this
would inevitably give rise to a signiÂ®cantly
reduced contact area in the epitope. It thus appears
that the much reduced afÂ®nity of the mAb A6 for
Figure 4. Ramachandran plot of the f/c torsion angles of the A6 Â± IFNgR1-108 complex produced by PROCHECK
(Laskowski et al., 1993). The glycine residues are indicated by triangles and all other residues by squares. The nonï¿¾glycine residues in disallowed regions are labeled.
888 Epitopes on the Interferon  Receptorthe mouse receptor, and mutant 6 of the homolog
scanning mutants (Table 1), results primarily from
the deletion of a signiÂ®cant part of the CC0 loop.
Homology modeling suggests that mutant 8
should have a similar conformation in the EF loop
region to the wild type. The large reduction in afÂ®-
nity of mutant 8 is difÂ®cult to rationalize in terms
of a perturbation of its direct contacts with A6. An
alternative explanation is an indirect effect of the
mutated residues on the conformation of the CC0
loop. For example, as seen in Figure 9(b), the sideï¿¾chain of AsnI79 hydrogen bonds to two backbone
NH groups and possibly to AsnI53. Its replacement
by valine would disrupt these interactions and
thereby destabilize the optimal conformation for
binding A6.
Several examples of the binding of a common
set of amino acid residues by different binding
sites with no or little similarity have been reported.
The structure of the complex between the monoï¿¾meric human growth hormone and its dimeric
receptor showed that the same set of residues on
the two receptor monomers binds to different parts
of the hormone (De Vos et al., 1992). Lescar et al.
(1995) found that two antibodies with low homï¿¾ology in the variable regions bind to almost the
same epitope of lysozyme. And the anti-hen egg
white lysozyme mAb D1.3 forms complexes with
lysozyme and the anti-D1.3 mAb E5.2 through
essentially the same combining site residues (Fields
et al., 1995). The relevance of these observations
has been discussed by Colman (1997) in the context
of viral antigenic variation. In all the above cases,
the structure of the region recognized by two
different `ligands' is essentially identical apart from
local conformational adjustments. In our case,
however, a rather dramatic conformational change
is observed, in which the tip of the receptor loop
(I51 and I52) is displaced over a distance of 8 AÃŠ ,
and the two `ligands' (mAb A6 and IFNg) therefore
recognize quite different structures formed by the
same receptor residues (Figure 9).
Comparisons with other Fab structures
The analysis of antibody fragments of known
structure has revealed that, with the exception of
CDR H3, the other Â®ve CDRs adopt preferred
main-chain conformations, or canonical structures
(Chothia et al., 1992, 1989). CDR H1 (canonical
structure H1:3) and H2 (canonical structure H2:1)
of A6 have similar sequences and backbone conforï¿¾mations to those in the HIV-1 neutralizing mAb
50.1 (Rini et al., 1993). The backbones (N, Ca
, C0
) of
CDR H1 (H26 to H35) and H2 (H50 to H65) of A6
and 50.1 can be superimposed with an r.m.s. deviï¿¾ation of 0.4 AÃŠ . CDR H3 of A6 is, however, seven
residues longer than that in Fab 50.1, and these
additional residues largely account for the quite
differently shaped combining sites of these two
mAbs.
Similarly, the backbone atoms of CDRs L1 (L24
to L34; canonical form L1:2) and L2 (L50 to L56) of
A6 can be superimposed together onto L1 and L2
of the anti-lysozyme mAb D1.3 (Fischmann et al.,
1991) with an r.m.s. deviation in the backbone
atoms of 0.35 AÃŠ . CDR L3 of A6, however, does
not correspond to the canonical forms 1, 2 or 3
identiÂ®ed for L3 loops by Chothia (1989). The
cause is the lack of Pro95 in this k L-chain. The
crystal structure of the Fab from mAb CRIS-1,
reported recently (Guarne et al., 1996), also lacks a
ProL95, and has the same CDR-L3 backbone conï¿¾formation as that seen in A6 (r.m.s. deviation over
L89 to L98 AÃŠ 0.23 AÃŠ ), which therefore appears to
constitute a new canonical structure for CDR L3
loops that lack ProL95.
Outlook
The results reported above raise several interestï¿¾ing questions concerning the mechanisms of cytoï¿¾kine and antibody recognition by the IFNgR.
Firstly, the quite different conformations of the CC0
loop seen in the complexes with IFNg and A6
suggest a considerable degree of local backbone
mobility in this region on the IFNgR surface. This
has implications also for those interested in the
homology modeling of cytokine receptors of undeï¿¾termined 3D structure. Another important issue is
the extent to which this local mobility plays a role
in the mechanism of ligand recognition. Unfortuï¿¾nately, no data on the structure or mobility of the
free IFNgR are available. From a structural viewï¿¾point, the conformation observed in the complex
with A6 appears more stable in the absence of a
ligand than the open conformation seen in the
complex with IFNg. A simple rigid-body docking
of receptor to ligand, in a lock-and-key-like process
appears unlikely. Secondly, the high concentration
of aromatic residues (Tyr, Trp and His) observed
Figure 5. MOLMOL (Koradi et al., 1996) diagram of the
A6 Â± IFNgR1-108 complex. Only the VH and VL regions of
the mAb A6 heavy and light chains are shown.
Epitopes on the Interferon  Receptor 889Figure 6. Linkage diagram of the antigen-antibody contacts upon complex formation. Bar height represents the area in ÃŠA2 of each amino acid covered by the other peptide
chain. The area is subdivided into the parts covered by polar atoms (Â®lled bars), by hydrophobic atoms (open bars) and by both mixed (stippled bars). Lines connect all
amino acid pairs where any two atoms contact each other; (a) contacts between the IFNgR1-108 and VH of the mAb A6; (b) Contacts between the IFNgR1-108 and VL of the
mAb A6. Intermolecular pairwise contacts and solvent-accessible surface areas were calculated using XSAE (C. Broger, personal communication) with a probe sphere of
1.4
ÃŠ
A and standard van der Waals radii. The Figure was produced by XSAE.at the interface of the A6 Â± IFNgR complex is noteï¿¾worthy and highlights the potential importance of
NH Â±aromatic hydrogen bonds, as well as other
effects, in stabilizing the complex. Since the extraï¿¾cellular IFNgR, IFNg and the antibody fragments
can be prepared conveniently, this system should
be amenable to a more detailed structure Â± function
analysis, which may shed light on the mechanisms
of ligandÂ± recognition by this receptor.
Materials and Methods
Secretion of the human IFNgR1-229 and mutants
in E. coli.
The extracellular portion of the wt human IFNgR (resiï¿¾dues 1 to 229) was produced by secretion into the periï¿¾plasm in E. coli HB2151. cDNA encoding the receptor
(Aguet et al., 1988) was ampliÂ®ed by PCR using primers
that include NcoI and NotI sites. The PCR product was
cloned after digestion with NcoI and NotI into the phageï¿¾mid pHEN1 (Hoogenboom et al., 1991) to afford
pOCI656. The receptor is thereby fused via a short -Ala3-
linker at its C terminus to a 14-residue peptide including
an epitope recognized by the anti-c-myc tag mAb 9E10
(Evan et al., 1985).
E. coli HB2151 transformed with phagemid encoding
wt IFNgR1-229 (or mutant) was selected on 2TY agar conï¿¾taining 1% glucose and 100 mg/ml ampicillin at 30C.
Colonies were transferred into 2TY (15 ml) containing
1% glucose and 100 mg/ml ampicillin and grown overï¿¾night at 30C. This medium (5 ml) was added to fresh
2TY medium (500 ml) again with glucose and ampicillin.
After growth at 30C to A550 Âˆ 0.5 to 1, the cells were
pelleted, resuspended in fresh 2TY medium with
100 mg/ml ampicillin and 0.01 mM IPTG. After growth
for 16 hours at 30C and centrifugation, the cells were
resuspended in Tris-HCl (100 mM, pH 8.0), 0.5 M
sucrose and 0.5 mM EDTA (1 ml). The same buffer solï¿¾ution (9 ml) containing lysozyme (2 mg/ml) was then
added, diluted with a further 20 ml buffer, and then
20 ml water was added together with PMSF (1 mM),
benzamidine (1 mM) and NaN3 (0.04%). After 20 minï¿¾utes, cells and debris were removed by centrifugation
and the supernatant was applied to an immunoafÂ®nity
column prepared by crosslinking mAb 9E10 to CNBrï¿¾activated Sepharose (Pharmacia). The column was
washed with sodium phosphate (50 mM, pH 7.0, 0.04%
NaN3), and bound protein was eluted with glycine-HCl
(50 mM, pH 2.5, 150 mM NaCl, 0.04% NaN3) and
immediately neutralized with sodium phosphate (4 M,
pH 7.0). The eluted protein was dialyzed against buffer
A (Tris-HCl, 25 mM, pH 8.0) and then chromatographed
on a Mono-Q HR 5/5 column (Pharmacia) with a gradiï¿¾ent from 0 to 65% buffer B (25 mM Tris-HCl, 0.5 M
NaCl, pH 8). The product was >95% homogeneous on
SDS-PAGE, and wt as well as all mutants gave the corï¿¾rect N-terminal amino acid sequence. The wt receptor
Figure 7. Stereo view of the A6 Â±
IFNgR1-108 interface (A6 and IFNgR
in thick and thin lines, respectï¿¾ively). Residues involved in antigen
Â± antibody contacts are labeled
with their sequence numbers. The
broken lines show interactions
listed in Table 3. The Figure was
produced by Moloc (Gerber &
MuÃˆller, 1995).
Figure 8. Residues at the A6 Â±
IFNgR interface; on the receptor
(bottom left, grey and turquoise),
and on A6 (top right) CDR L1
(light blue), L2 (dark blue), L3
(green), CDR H1 (yellow), H2
(orange) and H3 (red) (orientation
as in Figure 5). Figure was proï¿¾duced using MOLMOL (Koradi
et al., 1996).
Epitopes on the Interferon  Receptor 891and mutants 6 and 13 (Table 1) were analyzed by elecï¿¾trospray mass spectrometry, and gave peaks consistent
with the expected masses. The concentration of wt recepï¿¾tor was determined by quantitative amino acid analysis,
from which a molar extinction coefÂ®cient was deterï¿¾mined (e Âˆ 48,000 MÃ¿1 cmÃ¿1
) at 280 nm (A280). Sedimenï¿¾tation equilibrium analytical ultracentrifugation using a
20 mM solution of wt IFNgR1-229 in sodium phosphate
buffer (50 mM, pH 7.2) and NaCl (150 mM) gave a molï¿¾ecular mass of 26.9 kDa (calculated mass Âˆ 27.587 kDa),
and sedimentation data were consistent with a monoï¿¾meric native form. CD spectra of the wt and mutant
IFNgR proteins were recorded on a Jasco J720 instrument
at a protein concentration of 10 mM in sodium phosï¿¾phate buffer (10 mM, pH 7.2).
Mutagenesis of the IFNgR1-229
General cloning methods were as described by
Sambrook et al. (1989). A total of 24 of the 26 homolog
scanning mutants (Table 1) were prepared by mutagenï¿¾esis of IFNgR1-229 cDNA using PCR methods (Li &
Shapiro, 1993; Chen & Przybyla, 1994). This involved
using mutagenic primers encoding the changes required,
pOCI656 (vide supra) as template, and two invariant
Â¯anking primers that contain an NcoI site in the 50 priï¿¾mer and a NotI site in the 30 primer. The Â®nal PCR proï¿¾ducts were digested with NcoI and NotI and ligated
between the corresponding cloning sites in pHEN1. The
remaining two mutants (11 and 26) were also prepared
by PCR methods, using a mutagenic oligonucleotide as
the 30 primer in a standard PCR. Prior to expression,
each mutant (in the expression vector pHEN1) was
sequenced throughout the entire open reading frame, on
both DNA strands, using dye terminator chemistry (Perï¿¾kin Elmer), to conÂ®rm that only the desired nt changes
had been introduced.
BIAcore measurements
Measurements were carried out on a BIAcore instruï¿¾ment (Pharmacia Biosensor) at 25C, with PBS (50 mM
sodium phosphate buffer (pH 7.2), 150 mM NaCl) conï¿¾taining 0.005% (v/v) Surfactant-p20 as running buffer.
Protein was immobilized on CM5 sensor chips by ranï¿¾dom amine coupling, as described in the BIAcore
methods manual. Coupling was performed in sodium
acetate buffer (10 mM, pH 4.0) at a protein concentration
of 100 mg/ml (for mAbs) or 24 mg/ml (for receptor). The
level of immobilization corresponded typically to 500 to
1,000 resonance units (RU), which gave rise to Rmax
values on ligand binding of 70 to 200 RU. Around 10,000
RUs of gR99 were immobilized for determination of
active free receptor concentrations from initial binding
rates (mass transport-limited conditions) (Karlsson et al.,
1993). IFNg lacking the ten C-terminal residues
(IFNg10) (DoÃˆbeli et al., 1988) was used for binding
assays. Protein concentrations in stock solutions in PBS
(phosphate-buffered saline) were determined from A280
measurements after calibration by quantitative amino
acid analysis (1 mg/ml corresponds to: A280 Âˆ 1.7 for
IFNgR1-229; A280 Âˆ 1.35 for mAb; A280 Âˆ 1.0 for IFNg10),
and also for receptor from mass transport-limited initial
binding rates. A Â¯ow rate of 10 ml/min and an injection
volume of 30 ml were used routinely. The Â¯ow rate and
injection volume for protein determinations under mass
transport-limited conditions were 2 ml/min and 10 ml,
respectively. gR99 and IFNgR surfaces were regenerated
by injection of glycine buffer (10 ml, 0.1 M, pH 2.5). These
conditions were not suitable for regeneration of A6 or
gR38 surfaces. However, the relatively high koff for
receptor from these mAb surfaces enabled repeated use
without injection of complex-destabilizing solutions for
regeneration. The response returned fully to baseline
level within 5 to 15 minutes after the end of sample injecï¿¾tion. Analyte concentrations used for kinetic analyses
were: IFNg10 binding to immobilized IFNgR, 13 assays
in the range 10 to 500 nM; IFNgR binding to immobiï¿¾lized A6, 7 assays in the range 10 to 150 nM; IFNgR
binding to immobilized gR38, 7 assays in the range 20 to
300 nM; and IFNgR binding to immobilized gR99, seven
assays in range 10 to 100 nM. IFNgR mutants 6, 8, 13, 14
and 21 (see Table 1) with reduced afÂ®nity for mAbs were
analyzed at concentrations in the range 0.25 to 28 mM.
Mass transport-limiting gR99 surfaces were calibrated
using 5 to 50 nM wt receptor. The speciÂ®city of the mAb
surfaces was checked by injection of individual domains
of the IFNgR as fusion proteins with thioredoxin (Trx),
prepared as described (Williams et al., 1995). Trx-IFNgR1-
108 bound only to A6 and gR38 mAb surfaces, whereas
Trx-IFNgR100-229 recognised only the gR99 mAb surface.
SpeciÂ®city in binding to the IFNgR surface was veriÂ®ed
by injection of IFNg10 in admixture with IFNgR1-229,
Trx-IFNg1-108 or Trx-IFNgR100-229. As expected, only in
the latter two cases was binding observed. No backï¿¾ground binding was observed on injecting receptor or
IFNg10 over a blank CM5 sensor surface.
BIAcore data analysis
Binding curves were analyzed using BIAevaluation
software (version 2.1). KD values were calculated from
the ratio of dissociation (koff) to association (kon) rate conï¿¾stants. The baselines of sensorgrams were set to zero.
The koff values were derived by Â®tting a one-minute
period of the dissociation phase to the equation
(O'Shannessy et al., 1993):
R Âˆ R1eÃ¿koff Â…tÃ¿t1Â†
R, response in RUs, t, time in seconds; t1, start time for
dissociation; R1, response at t1. The kon values were calï¿¾culated by Â®tting the response during sample injection to
the equation:
Table 3. Potential hydrogen bonding interactions in the
antigen Â± antibody interface (cut-off distance 3.5 AÃŠ )
IFNgR1-108 A6VH Distance (AÃŠ ) A6VL Distance (AÃŠ )
CC0 loop
K47 NZ W92 O 2.8
Y49 OH G100 O 2.5
Y49 OH H100B ND1 3.1
G50 O G100 N 3.2
G50 O R95 NH2 3.3
V51 O R95 NH1 2.9
V51 O H100B NE2 3.0
K52 NZ D54 OD2 2.8
K52 NZ D56 OD2 2.8
N53 O T94 N 2.9
N53 ND2 T94 O 3.3
N53 ND2 Y91O 3.2
S54 O S93 OG 3.2
EF loop
D76 OD1 Y32 OH 3.1
D76 OD2 Y32 OH 3.1
S78 O Y99 OH 2.7
892 Epitopes on the Interferon  ReceptorR Âˆ ReqÂ‰1 Ã¿ eksÂ…tÃ¿toÂ†
ÂŠ
Req, steady state response level; ks Âˆ konC Â‡ koff, where C
is the molar concentration of the injected analyte to, start
time for association. A plot of ks against C yields a
straight line with a slope equivalent to kon. The standard
deviation in the kinetic parameters was <25% between
repeated analyses with different preparations of the
same protein.
BIAcore analyses of wt IFNgR, in which levels of
immobilized protein and analyte Â¯ow rates were varied,
showed that mass transport limitation had insigniÂ®cant
effects on the calculated kinetic parameters. Several
mutants showed koff values >0.02 sÃ¿1
, and for these
cases a second method of determining KD was used. The
steady state binding response (Req) was measured and
KA (1/KD) was derived from Â®tting a plot of Req against
analyte concentration, according to the equation
(Karlsson et al., 1991):
Req Âˆ KACRmax=KAC Â‡ 1
koff could then be calculated by dividing kon by KA.
The use of high levels of immobilized gR99 resulted in
linear initial binding rates (ro) for the receptor in the conï¿¾centration range 5 to 50 nM. The concentrations of active
mutant proteins could then be determined using a caliï¿¾bration curve of ro against concentration for wt receptor
(Karlsson et al., 1993). The active concentration of most
mutants was similar to the concentration determined
spectrophotometrically. The active concentration of
mutants with decreased afÂ®nity for gR99 could not be
determined in this manner.
Formation and purification of the A6
Fab-IFNggR1-108 complex
The mAb A6 was digested with pepsin in sodium
acetate buffer (100 mM, pH 4.0). Upon complete digesï¿¾tion, the pH was adjusted to 8.0 with Tris, and cysteine
(20 mM) was added. After 30 minutes, iodoacetamide
was added (30 mM), and the Fab was puriÂ®ed by Protein
G afÂ®nity chromatography, by elution through a Monoï¿¾Q HR 5/5 column (gradient with buffer A (ethanolaï¿¾mine-HCl (25 mM, pH 9.3)), and buffer A plus NaCl (0.5
M)), and Â®nally using a Mono-P 5/20 column (gradient
with buffer A, and buffer A with polybufferHCl (Pharï¿¾macia), pH 7.0). The IFNgR1-108 was prepared as
described (Williams et al., 1995), and mixed in 50%
Figure 9. (a) Stereo view of a
comparison of the structure of
IFNgR1-108 as observed in the A6 Â±
IFNgR1-108 complex with that seen
in a IFNgÂ± IFNgR complex strucï¿¾ture containing a mutant hormone
and recently solved at 2.0 AÃŠ resolï¿¾ution (Randal & A. A. Kossiakoff,
unpublished data). Ca superposiï¿¾tion of IFNgR1-108 (thick lines) with
the receptor domain from the
IFNgÂ± IFNgR complex (thin lines)
was based on 83 of the 94 common
residues (r.m.s. distance 0.64 AÃŠ ).
(b) Conformation of the CC0 loop
of IFNgR1-108 with some residues of
the adjacent F strand. The Ca trace
of the corresponding residues from
the superimposed IFNgÂ± IFNgR
complex is shown in thin lines.
Hydrogen bonds within this loop
and with strand F that are only
possible in the more closed conforï¿¾mation observed here are indicated.
The Figure was produced using
Moloc (Gerber & MuÃˆller, 1995).
Epitopes on the Interferon  Receptor 893excess with the A6 Fab. The complex was puriÂ®ed by gel
Â®ltration (Superose-12) eluting with Tris (0.1 M, pH 8),
NaCl (100 mM, EDTA (2 mM), IFNgR1-108 (50 nM) and
NaN3 (0.08% w/v), and concentrated to 20 mg/ml in
Tris (25 mM, pH 8.0), NaCl (25 mM) and EDTA
(0.5 mM) for crystallization.
Crystallization and data collection
Crystals of the complex were grown by the hangingï¿¾drop vapor diffusion method at room temperature and
reached a maximum size of 0.4 mm  0.3 mm  0.3 mm.
Droplets (3 ml) of protein solution mixed with 0.5 ml
reservoir solution were equilibrated against a reservoir
containing 10% (w/v) PEG ME 5000, NaCl (0.5 M) bufï¿¾fered with Bis/Tris (50 mM, pH 5.5). The diffraction data
were collected using an imaging plate detector (MarReï¿¾search) mounted on a FR591 rotating anode X-ray genï¿¾erator (Enraf) equipped with focusing mirror optics
(Supper). For data collection, a crystal was soaked for a
few minutes in a buffer containing 30% glycerol in
addition to the components of the reservoir, picked up in
a small loop, shock-frozen in liquid nitrogen and transï¿¾ferred into a nitrogen gas stream (120 K; Oxford Cryoï¿¾system) on the Mar goniostat. Indexing and integration
of the diffraction data (400 frames of 0.25, 600 s/frame)
were performed by the MARXDS program package
(Kabsch, 1988). The rather dramatic fall off in the difï¿¾fracted X-ray intensity beyond 3.2 AÃŠ resolution made
long exposure times necessary to obtain acceptable statï¿¾istics in the highest resolution ranges (Table 4). A Wilson
(1949) plot with data between 6.0 and 2.82 AÃŠ yields an
intrinsic temperature factor of 58 AÃŠ 2 for these crystals.
There is one molecule of the complex per asymmetric
unit corresponding to a VM of 3.1 AÃŠ 3
/Da (Matthews,
1968).
Structure solution and refinement
The structure of the complex was solved by the molï¿¾ecular replacement method using AMoRe (Navaza,
1994). In order to Â®nd the best search models, a sequence
homology search was done comparing the VH, VL, CH1
and CL domain sequences of mAb A6 (Bridges et al.,
1995) with the corresponding domain sequences of Fab
structures available from the Brookhaven Protein Data
Bank (Bernstein et al., 1977). For the Fv part the highest
sequence identities were found with VH of Fab 50.1 (80%
identity; entry code 1GGB; Rini et al., 1993) and VL of
Fab B72.3 (65% identity; entry code 1BBJ; Brady et al.,
1992). The search model of this part was constructed
using the in-house modeling program Moloc having its
own force Â®eld for energy minimization (Gerber &
MuÃˆller, 1995). First, the Fv of 50.1 was superimposed
onto the Fv of B72.3 and one domain of each was then
chosen so as to make the chimeric Fv with the highest
homology to A6. Subsequently, all side-chains different
from the mAb A6 sequence were corrected and residual
strain removed through energy minimization using
Moloc. CDR H3 was not present in Fab 50.1 and the corï¿¾responding residues H95 to H102 of mAb A6 were thus
omitted from the search model. The Fchl part was
assumed to be identical in sequence to that present in
Fab HyHEL-5, entry code 2HFL (Sheriff et al., 1987) and
was thus taken unchanged from this structure. A preï¿¾liminary model for IFNgR1-108 (missing residues I1 to I10
and I89 to I93) was available from the structure determiï¿¾nation of the IFNgÂ±IFNgR complex (CheÃ‚ne et al., 1995;
le Du et al., unpublished data).
Rotation and translation searches were Â®rst carried
out separately for the Fv and Fchl models with diffracï¿¾tion data in the range 10 to 3.5 AÃŠ . The search with Fv
yielded one clearly best solution. The top rotation funcï¿¾tion peak had a signal of 15.9 s (8.9 s for the second
peak) and yielded a correlation coefÂ®cient of 0.32 and
R-factor of 0.51 in the translation function search (0.22
and 0.54 for the second peak). Similar searches with
Fchl alone were inconclusive. However, including the
Fv solution in Fchl translation searches with the top ten
Fchl rotation peaks yielded the best translation function
solution for the top rotation function peak (8.2 s). After
rigid body reÂ®nement in AMoRe the correlation coefÂ®-
cient was 0.37 and the R-factor 0.49. Although the
improvement in the R-factor appeared marginal the corï¿¾rectness of this solution was strongly supported by the
fact that the Fv and Fchl fragments joined up in preï¿¾cisely the way expected for a Fab fragment. Attempts to
determine the position of IFNgR1-108 by molecular replaï¿¾cement methods using the known Fv and Fchl positions
in the translation search were unsuccessful.
Subsequent structure reÂ®nement was carried out with
X-Plor (BruÃˆ nger, 1992b) and model building using Moloc
and O (Jones et al., 1991). Rigid-body optimization of the
four Fab domains (VH, VL, CL and CH1) using diffraction
data between 10 and 3.5 AÃŠ resolution followed by posï¿¾itional reÂ®nement and some minor model corrections
reduced the R-factor to 0.40. A subsequent sigmaï¿¾weighted electron density map (Read, 1986) revealed
Table 4. Summary of X-ray data collection statistics
Resolution (AÃŠ ) Number of reflections Average Completeness (%) Rsym (%)
a
Min Max Observed Unique I/sigma (I) Shell Shell
19.86 8.16 2,837 821 62.00 89.9 2.15
8.16 6.03 4,626 1,251 52.77 99.5 3.04
6.03 5.00 5,960 1,541 51.32 99.8 2.80
5.00 4.36 7,099 1,815 51.24 99.6 3.00
4.36 3.92 7,813 1,991 41.09 99.6 4.37
3.92 3.59 8,541 2,200 31.64 99.4 6.66
3.59 3.33 9,242 2,389 23.66 98.8 9.84
3.33 3.12 9,739 2,542 15.39 99.2 15.37
3.12 2.95 9,992 2,621 10.55 99.7 22.29
2.95 2.82 8,975 2,465 7.52 98.1 28.78
19.86 2.82 74,824 19,636 29.65 98.8 5.88
Space group P212121, a Âˆ 85.7, b Âˆ 90.8, and c Âˆ 101.6 AÃŠ at 120 K. a Rsym Âˆ hi
|Ih,i Ã¿ Ih|/hi
Ih,i.
894 Epitopes on the Interferon  Receptor  extra density into which the available IFNgR1-108
model could be positioned unambiguously. Rigid-body
reÂ®nement of the now Â®ve domains (VH, VL, CL, CH and
IFNgR1-108) was then followed by a number of cycles
comprising model (re)building, positional reÂ®nement
(using the parameters of Engh & Huber (1991)) and
reÂ®nement of individual B-factors. The free R-factor (5%
of the data) was used to monitor and verify improveï¿¾ments during reÂ®nement of the model. In the course of
this procedure two regions missing in the search model
could be unambiguously built and were added to the
model (CDR H3 and I89 to I93). Major model rebuilding
was indicated in loop I47-I56 of IFNgR1-108 and a simuï¿¾lated annealing omit electron density (BruÃˆ nger, 1992a)
for this region is shown in Figure 10. Consistent with
the poor signal of the Fchl part observed in the molecuï¿¾lar replacement searches, the B-factors of the atoms of
the CL and CH1 domains reÂ®ned to rather high values.
The electron density for the whole Fchl part was weak,
fragmented in many areas and completely missing for
most residues of surface loops. Therefore, only the best
determined chain segments with continuous electron
density were retained from these two domains (see
Table 2). Another three disordered residues were
removed from the C terminus of the receptor domain.
Finally, a small number of water molecules were
assigned to the strongest difference Fourier peaks on the
surface of the three well-deÂ®ned domains taking hydroï¿¾gen bonding criteria into consideration. A bulk solvent
correction as available in X-Plor was used throughout
reÂ®nement using values of 0.25 AÃŠ , 0.35 e/AÃŠ 3 and 50 AÃŠ 2
for the parameters solrad, solden and the smoothing Bï¿¾factor respectively as described in detail by Kostrewa
et al. (1997). The reÂ®ned coordinates have been deposï¿¾ited with the Brookhaven Data Bank, accession code
1jrh.
Acknowledgements
We thank Steve Ealick, Dan Thiel and Marie le Du for
providing the coordinates of their independent structure
determination of the IFNgÂ± IFNgR complex (used for
initial model building and to produce Figures 1 and 3),
Mike Randal and Tony Kossiakoff (Genentech Inc.) for
providing the coordinates of IFNgR from a recent 2.0 AÃŠ
structure determination of a IFNgÃ IFNgR complex conï¿¾taining a mutant hormone (used to produce Figure 9),
Dr R. Gentz for providing recombinant IFNgR from
an insect cell expression system, Klaus HofstaÃˆdter for
providing IFNgR1-108, Dr R. Thomas (Department of
Polymer Chemistry, ETH-Z) for performing the sedimenï¿¾tation equilibrium analytical ultracentrifugation analysis,
Dr Ignasi Fita for providing the atomic coordinates of
the CRIS-1 Fab, and Annelies Meier for technical assistï¿¾ance.
This work was supported by grants from the Swiss
National Science Foundation.
References
Aguet, M., Dembic, Z. & Merlin, G. (1988). Molecular
cloning and expression of the human interferon-g
receptor. Cell, 55, 273 Â± 280.
Aguet, M. & Merlin, G. (1987). PuriÂ®cation of human g
interferon receptors by sequential afÂ®nity chromaï¿¾tography on immobilized monoclonal antireceptor
antibodies and human g interferon. J. Expt. Med.
165, 988 Â± 999.
Bach, E. A., Aguet, M. & Schreiber, R. D. (1997). The
IFNg receptor: A paradigm for cytokine signaling.
Annu. Rev. Immunol. 15, 563 Â± 591.
Banner, D. W., D'Arcy, A., CheÃne, C. & Winkler, F. K.
(1996). The crystal structure of the complex of
blood coagulation factor VIIa with soluble tissue
factor. Nature, 380, 41 Â± 46.
Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer,
E. F., Brice, M. D., Rodgers, J. R., Kennard, O.,
Shimanouchi, T. & Tasumi, M. (1977). The protein
data bank: a computer-based archival Â®le for
macromolecular structures. J. Mol. Biol. 112, 535 Â±
542.
Brady, R. L., Edwards, D. J., Hubbard, R. E., Jiang, J. S.,
Lange, G., Roberts, S. M., Tood, R. J., Adair, J. R.,
Emtage, J. S., King, D. J. & Low, D. C. (1992). Crysï¿¾tal structure of a chimeric Fab' fragment of an antiï¿¾body binding tumour cells. J. Mol. Biol. 227, 253 Â±
264.
Bridges, A., Birch, A., Williams, G., Aguet, M., Schlatter,
D., Huber, W., Garotta, G. & Robinson, J. A. (1995).
Variable region cDNA sequences and characterizï¿¾ation of murine anti-human interferon g receptor
monoclonal antibodies that inhibit receptor binding
by interferon g. Mol. Immunol. 32, 1329Â± 1338.
Figure 10. Stereo view showing a
simulated annealing Fo Ã¿ Fc omit
electron density map for residues
I47 to I56 of IFNgR1-108 together
with the reÂ®ned model at 2.8 AÃŠ resï¿¾olution. The map was contoured at
1.0 s. The Figure was produced
using Moloc (Gerber & MuÃˆller,
1995).
Epitopes on the Interferon  Receptor 895Bridges, A., Stuart, F., SpaÃˆth, J., Lang, S., Henke, C.,
Birch, A. & Robinson, J. A. (1996). Production and
characterization of anti-human interferon g receptor
antibody fragments that inhibit cytokine binding to
the receptor. Protein Eng. 9, 365Â±370.
BruÃˆ nger, A. T. (1992a). Free R value: a novel statistical
quantity for assessing the accuracy of crystal
structures. Nature, 355, 472Â±475.
BruÃˆ nger, A. T. (1992b). X-PLOR Version 3.1, A System
For X-ray Crystallography and NMR, Yale University
Press, New York.
Chen, B. & Przybyla, A. E. (1994). An efÂ®cient siteï¿¾directed mutagenesis method based on PCR. Bioï¿¾Techniques, 17, 657Â±659.
CheÃ‚ne, C., Fountoulakis, M., DoÃˆbeli, H., D'Arcy, B.,
Winkler, F. & D'Arcy, A. (1995). Crystallization of
the complex of human IFN-g and the extracellular
domain of the IFN-g receptor. Protein: Struct, Funct.
Genet. 23, 591Â±594.
Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M.,
Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A.,
Davies, D., Tulip, W. R., Colman, P. M., Spinelli, S.,
Alzari, P. M. & Poljak, R. J. (1989). Conformations
of immunoglobulin hypervariable regions. Nature,
342, 877Â±883.
Chothia, C., Lesk, A. M., Gherardi, E., Tomlinson, I. M.,
Walter, G., Marks, J. D., Llewelyn, M. B. & Winter,
G. (1992). Structural repertoire of the human VH
segments. J. Mol. Biol. 227, 799Â±817.
Colman, P. M. (1997). Virus versus antibody. Structure,
5, 591Â±593.
Cunningham, B. C., Jhurani, P., Ng, P. & Wells, J. A.
(1989). Receptor and antibody epitopes in human
growth hormone identiÂ®ed by homolog-scanning
mutagenesis. Science, 243, 1330Â±1336.
Davies, D. R. & Cohen, G. H. (1996). Interactions of proï¿¾tein antigens with antibodies. Proc. Natl Acad. Sci.
USA, 93, 7Â±12.
De Vos, A. M., Ultsch, M. & Kossiakoff, A. A. (1992).
Human growth hormone and extracellular domain
of its receptor: crystal structure of the complex.
Science, 255, 306Â±312.
DoÃˆbeli, H., Gentz, R., Jucker, W., Garotta, G., Hartmann,
D. W. & Hochuli, E. (1988). Role of the carboxyï¿¾terminal sequence on the biological activity of
human immune interferon (IFN-g). J. Biotechnol. 7,
199Â±216.
Engh, R. A. & Huber, R. (1991). Accurate bond and
angle parameters for X-ray protein structure
reÂ®nement. Acta Crystallog. sect. A, 47, 392Â±400.
Evan, G. I., Lewis, G. K., Ramsay, G. & Bishop, J. M.
(1985). Isolation of monoclonal antibodies speciÂ®c
for human c-myc proto-oncogene product. Mol. Cell.
Biol. 5, 3610Â±3616.
Fields, B. A., Goldbaum, F. A., Ysern, X., Poljak, R. J. &
Mariuzza, R. A. (1995). Molecular basis of antigen
mimicry by an anti-idiotiope. Nature, 374, 739Â±742.
Fischmann, T. O., Bentley, G. A., Bhat, T. N., Boulot, G.,
Mariuzza, R. A., Phillips, S. E. V., Tello, D. &
Poljak, R. J. (1991). Crystallographic reÂ®nement
of the three-dimensional structure of the Fab
D1.3-lysozyme complex at 2.5-AÃŠ resolution. J. Biol.
Chem. 266, 12915Â±12920.
Fountoulakis, M. & Genz, R. (1992). Effect of glycosylaï¿¾tion on properties of soluble interferon gamma
receptors produced in prokaryotic and eukaryotic
expression systems. BioTechnol. 10, 1143Â±1147.
Garotta, G., Ozmen, L., Fountoulakis, M., Dembic, Z.,
Van Loon, A. P. G. M. & StuÃˆ ber, D. (1990). Human
interferon-g receptor. Mapping of epitopes recogï¿¾nized by neutralizing antibodies using native and
recombinant proteins. J. Biol. Chem. 265, 6908Â±6915.
Gentz, R., Hayes, A., Grau, N., Fountoulakis, M., Lahm,
H.-W., Ozmen, L. & Garotta, G. (1992). Analysis of
soluble human and mouse interferon-g receptors
expressed in eukaryotic cells. Eur. J. Biochem. 210,
545Â±554.
Gerber, P. R. & MuÃˆller, K. (1995). MAB, a generally
applicable molecular force Â®eld for structure modelï¿¾ling in medicinal chemistry. J. Comput.-Aid. Mol.
Des. 9, 251Â±268.
Guarne, A., Bravo, J., Calvo, J., Lozano, F., Vives, J. &
Fita, I. (1996). Conformation of the hypervariable
region l3 without the key proline residue. Protein
Sci. 5, 167Â±169.
Haelewyn, J., Michiels, L., Verhaert, P., Hoylaerts, M. F.,
Witters, R. & De Ley, M. (1997). Interaction of trunï¿¾cated human interferon g variants with the interï¿¾feron g receptor: crucial importance of Arg-129.
Biochem. J. 324, 591Â±595.
Harlos, K., Martin, D. M. A., O'Brien, D. P., Jones, E. Y.,
Stuart, D. I., Polikarpov, I., Miller, A., Tuddenham,
E. G. D. & Boys, C. W. (1994). Crystal structure of
the extracellular region of human tissue factor.
Nature, 370, 662Â±666.
Hoogenboom, H. R., GrifÂ®ths, A. D., Johnson, K. S.,
Chiswell, D. J., Hudson, P. & Winter, G. (1991).
Multi-subunit proteins on the surface of Â®lamentous
phage: methodologies for displaying antibody (Fab)
heavy and light chains. Nucl. Acids Res. 19, 4133Â±
4137.
Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M.
(1991). Improved methods for building protein
models in electron density maps and the location of
errors in these models. Acta Crystallog. sect. A, 47,
110Â±119.
Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S. &
Foeller, C. (1991). Sequences of Proteins of Immunoï¿¾logical Interest, 5th edit., U.S. Department of Health
and Human Services.
Kabsch, W. (1988). Evaluation of single-crystal X-ray difï¿¾fraction data from a position-sensitive detector.
J. Appl. Crystrallog. 21, 916Â±924.
Karlsson, R., Michaelsson, A. & Mattsson, L. (1991). Kinï¿¾etic analysis of monoclonal antibody-antigen interï¿¾actions with a new biosensor based analytical
system. J. Immunol. Meth. 145, 229Â±240.
Karlsson, R., FaÃˆgerstam, L., Nilshans, H. & Persson, B.
(1993). Analysis of active antibody concentrations.
Separation of afÂ®nity and concentration parameters.
J. Immunol. Meth. 166, 75Â±84.
Koradi, R., Billeter, M. & WuÃˆthrich, K. (1996). MOLï¿¾MOL: A program for display and analysis of
macromolecular structures. J. Mol. Graph. 14, 51Â±55.
Kossiakoff, A., Somers, W., Ultsch, M., Andow, K.,
Muller, Y. A. & De Vos, A. M. (1994). Comparison
of the intermediate complexes of human growth
hormone bound to the human growth hormone
and prolactin receptors. Protein Sci. 3, 1697Â±1705.
Kostrewa, D., GruÃˆ ninger-Leitch, F., D'Arcy, A., Broger,
C., Mitchell, D. & van Loon, A. P. G. M. (1997).
Crystal structure of phytase from Aspergillus Â®cuum
at 2.5 AÃŠ resolution. Nature Struct. Biol. 4, 185Â±190.
Laskowski, R. A., MacArthur, M. W., Moss, D. S. &
Thornton, J. M. (1993). PROCHECK: a program to
check the stereochemical quality of protein
structures. J. Appl. Crystallog. 26, 283Â±291.
896 Epitopes on the Interferon  ReceptorLescar, J., Pellegrini, M., Souchon, H., Tello, D., Poljak,
R. J., Peterson, N., Greene, M. & Alzari, P. M.
(1995). Crystal structure of a cross-reaction complex
between Fab F9.13.7 and guinea fowl lysozyme.
J. Biol. Chem. 270, 18067Â±18076.
Levitt, M. & Perutz, M. F. (1988). Aromatic rings act as
hydrogen bond acceptors. J. Mol. Biol. 201, 751Â±754.
Li, X.-M. & Shapiro, L. J. (1993). Three-step PCR mutaï¿¾genesis for `linker scanning'. Nucl. Acids Res. 21,
3745Â±3748.
Livnah, O., Stura, E. A., Johnson, D. L., Middleton, S. A.,
Mulcahy, L. S., Wrighton, N. C., Dower, W. J.,
Jolliffe, L. K. & Wilson, I. A. (1996). Functional
mimicry of a protein hormone by a peptide agonist:
the EPO receptor complex at 2.8 AÃŠ . Science, 273,
464Â±471.
Marsters, S. A., Pennica, D., Bach, E., Schreiber, R. D. &
Ashkenazi, A. (1995). Interferon g signals via a
high-afÂ®nity multisubunit receptor complex that
contains two types of polypeptide chain. Proc. Natl
Acad. Sci. USA, 92, 5401Â±5405.
Matthews, B. W. (1968). Solvent content of protein
crystals. J. Mol. Biol. 33, 491Â±497.
Muller, Y. A., Ultsch, M. H., Kelley, R. F. & de Vos,
A. M. (1994). Structure of the extracellular domain
of human tissue factor: location of the factor VIIa
binding site. Biochemistry, 33, 10964Â±10870.
Navaza, J. (1994). AMoRe: an automated package for
molecular replacement. Acta Crystallog. A50, 157Â±
163.
O'Shannessy, D. J. & Winzor, D. J. (1996). Interpretation
of deviations from pseudo-Â®rst-order kinetic behaï¿¾viour in the characterization of ligand binding by
biosensor technology. Anal. Biochem. 236, 275Â±283.
O'Shannessy, D. J., Brigham-Burke, M., Soneson, K. K.,
Hensley, P. & Brooks, I. (1993). Determination of
rate and equilibrium constants for macromolecular
interactions using surface plasmon resonance: use
of nonlinear least squeares analysis methods. Anal.
Biochem. 212, 457Â±468.
Padlan, E. A. (1990). On the nature of antibody combinï¿¾ing sites: unusual structural features that may conï¿¾fer on these sites an enhanced capacity for binding
ligands. Proteins, 7, 112Â±124.
Read, R. J. (1986). Improved Fourier coefÂ®cients for
maps using phases from partial structures with
errors. Acta Crystallog. sect. A, 42, 140Â±149.
Rini, J. M., StanÂ®eld, R. L., Stura, E. A., Salinas, P. A.,
Profy, A. T. & Wilson, I. A. (1993). Crystal structure
of a human immunodeÂ®ciency virus type 1 neutraï¿¾lizing antibody 50.1 in complex with its V3 loop
peptide antigen. Proc. Natl Acad. Sci. USA, 90,
6325Â±6329.
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecuï¿¾lar Cloning: A Laboratory Manual, Cold Spring Harï¿¾bor Laboratory Press, Cold Spring Harbor, NY.
Schreuder, H., Tardif, C., Trump-Kallmeyer, S.,
SofÂ®entini, A., Sarubbi, E., Akeson, A., Bowlin, T.,
Yanofsky, S. & Barrett, R. W. (1997). A new cytoï¿¾kine-receptor binding mode revealed by the crystal
structure of the IL-1 receptor with an antagonist.
Nature, 386, 194Â±200.
Sheriff, S., Silverton, E. W., Padlan, E. A., Cohen, G. H.,
Smith-Gill, S. J., Finzel, B. C. & Davies, D. R. (1987).
Three-dimensional structure of an antibody-antigen
complex. Proc. Natl Acad. Sci. USA, 84, 8075Â±8079.
Somers, W., Ultsch, M., Devos, A. M. & Kossiakoff,
A. A. (1994). The x-ray structure of a growth horï¿¾mone prolactin receptor complex. Nature, 372, 478Â±
481.
Vigers, G. P. A., Anderson, L. J., Caffes, P. &
Brandhuber, B. J. (1997). Crystal structure of the
type-I interleukin-1 receptor complexed with interï¿¾leukin-1Ã». Nature, 386, 190Â±194.
Walter, M. R., Windsor, W., Nagabhushan, T. L.,
Lundell, D. J., Lunn, C. A., Zauodny, P. J. &
Narula, S. K. (1995). Crystal structure of a complex
between interferon-gamma and its soluble high-afÂ®-
nity receptor. Nature, 376, 230Â±235.
Williams, G., Ruegg, N., Birch, A., Weber, C.,
Hofstadter, K., Robinson, J. A., Aguet, M., Garotta,
G., Schlatter, D. & Huber, W. (1995). Dissection of
the extracellular human interferon gamma receptor
alpha-chain into two immunoglobulin-like domains.
Production in an Escherichia coli thioredoxin gene
fusion expression system and recognition by neutraï¿¾lizing antibodies. Biochemistry, 34, 1787Â±1797.
Wilson, A. J. C. (1949). The probability distribution of
X-ray intensities. Acta Crystallog. 2, 318Â±321.
Edited by R. Huber
(Received 15 May 1997; received in revised form 4 August 1997; accepted 5 August 1997)
Epitopes on the Interferon  Receptor 897